October 2015- Volume 11, Issue 10

October 2015

In this Issue

Clinical Trials

Time keeps on ticking

Time keeps on ticking

Cycle time reduction remains elusive, according to KMR Group’s annual cycle time trends analysis

Taking time and money out of clinical trials

Taking time and money out of clinical trials

ICON and IBM plan to revolutionize clinical trial feasibility, patient recruitment and study start-up timelines

Biogen licenses Mitsubishi’s MT-1303 for autoimmune diseases

Biogen licenses Mitsubishi’s MT-1303 for autoimmune diseases

Potential exists for development of the therapeutic in multiple sclerosis, ulcerative colitis and Crohn’s disease

Moving forward on HIV

Moving forward on HIV

CytoDyn’s PRO 140, first self-injectable treatment for HIV patients, heads to Phase 3 and could go commercial by 2017

Adocia, Lilly advance BioChaperone Lispro into Phase 1b study

Adocia, Lilly advance BioChaperone Lispro into Phase 1b study

The companies will evaluate the effects of multiple daily doses of Adocia’s ultra-rapid insulin product in type 1 diabetics

OSE reports Phase 2 results with Tedopi

OSE reports Phase 2 results with Tedopi

Company unveils clinical and immunological outcomes in patients with brain metastases

Q&A

Q&A: Big Data for oncology

Q&A: Big Data for oncology

Oncology Research Information Exchange Network could make huge steps to bring together oncology research, oncology patients and drug developers

Preclinical

Setting the stage for development

Setting the stage for development

Rounding up some recent news of preclinical studies and results around the world A quartet of brief stories to give you a quick peek across the globe (a few select portions, anyway) into what researchers have turned up in preclinical efforts in recent months.

NCI grant pushes forward bone cancer research

NCI grant pushes forward bone cancer research

Though most common bone cancer in children, osteosarcoma’s rarity limits study funding

Dismantling viruses

Dismantling viruses

NanoViricides reports two successful studies of topical antiherpes treatment in animal models

Hope or hype for spinal injuries?

Hope or hype for spinal injuries?

Asterias announces preclinical data supporting the safety and use of AST-OPC1 as a treatment for spinal cord injury

A model mouse

A model mouse

Probiodrug licenses transgenic Alzheimer’s mouse model to QPS Austria Neuropharmacology

Research & Development

Jackson Lab launches precision genetics center

Jackson Lab launches precision genetics center

Center’s mission is to create disease models to develop therapies for life-threatening and genetically complex conditions

Inflammation intervention

Inflammation intervention

Botanisol wins NIH grant for anti-inflammatory compound that could bypass side effects of NSAIDs

Two advances in sequencing prep

Two advances in sequencing prep

Roche and Lumora make a deal and Fluidigm enhances its C1 system

Invoking Fitzgerald

Invoking Fitzgerald

Scripps Florida scientists’ structural discoveries could aid in better drug design

Contract Services

Navitas introduces new regulatory process outsourcing model

Navitas introduces new regulatory process outsourcing model

Move is driven in large part by pressure on pharmas and biotechs to do more regulatory work even as budgets tighten

goBalto making tracks with platform adoption

goBalto making tracks with platform adoption

More than 2,000 CROs and pharma firms now employ the company’s Activate software-as-a-service application

Contractual matters

Contractual matters

An overview of recent news on the CRO and CMO fronts

No seven-year itch for CRO

No seven-year itch for CRO

At over $158 million, Rho nets its largest federal contract ever

Business & Government Policy

Toward a total solution

Toward a total solution

Roche acquires Kapa Biosystems to boost next-gen sequencing product offerings

A partner for the global stage

A partner for the global stage

Apricus sends out the call for global development partner for Femprox

For your approval

For your approval

A collection of recent regulatory approvals and actions globally

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

The XF factor

The XF factor

California’s Agilent to acquire Massachusetts-based Seahorse Bioscience and its assay kits for measuring cell metabolism for $235 million

Editor's Focus

Commentary

Reader discretion is advised

Reader discretion is advised

Differences of opinion should be part of life, but perhaps they are not allowed as much freedom anymore as they should be

Guest Commentary: Defeating lupus starts with a diagnosis

Guest Commentary: Defeating lupus starts with a diagnosis

One of the challenges at the heart of tackling systemic lupus erythematosus is the intense difficulty associated with reaching an accurate diagnosis early in the disease, and there are ways we can start doing that

Discovery

MorphoSys and Immatics ally in immuno-oncology field

MorphoSys and Immatics ally in immuno-oncology field

Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins

Genetic trigger for obesity discovered

Genetic trigger for obesity discovered

South Australian researchers find unexpected potential in MNK gene

Cancer answers in the South Pacific

Cancer answers in the South Pacific

Yabao Pharmaceuticals and University of South Australia collaborate on joint drug discovery laboratory.

Discovery boom in Southern California

Discovery boom in Southern California

UCSD releases news on a trio of studies that have promise for drug discovery efforts

Special Reports

Diagnostics

Roche acquires GeneWEAVE

Roche acquires GeneWEAVE

GeneWEAVE’s Smarticles technology enhances Roche’s diagnostics role in fighting drug-resistant bacteria

Muddy waters for cancer detection?

Muddy waters for cancer detection?

Study of multigene panel raises questions about heredity risk of breast and ovarian cancer

A pan-Pacific partnership

A pan-Pacific partnership

Burning Rock, Illumina ink molecular diagnostics deal
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue